Home > Urology > EAU 2020 > Renal Cancer > KEYNOTE-426: no QoL differences pembrolizumab + axitinib versus sunitinib

KEYNOTE-426: no QoL differences pembrolizumab + axitinib versus sunitinib

The open-label, phase 3 KEYNOTE-426 trial demonstrated a significant survival advantage for patients with metastatic renal-cell carcinoma (mRCC) across all risk groups who received pembrolizumab with axitinib compared with those who received sunitinib. Prof. Jens Bedke (University of Tübingen, Germany) presented results of the patient-reported outcome analyses in which no evidence was found of a clinically important difference in quality of life (QoL) between the 2 study arms at any point during the 30 weeks of examination [1].

With a median follow-up of 30.6 months, KEYNOTE-426 demonstrated that pembrolizumab and axitinib (n=432) had a significant benefit compared with sunitinib (n=429) in mRCC patients in terms of overall survival (HR 0.68; 95% CI 0.55-0.85), progression-free survival (HR 0.71; 95% CI 0.60-0.84), and objective response rate (60% vs 40%). Key endpoints regarding the patient-rep...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on